ArticleCanadian journal of gastroenterology = Journal canadien de gastroenterologie2010
Health care costs associated with hepatitis C: a longitudinal cohort study.
Article in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review.PharmacoEconomics · 2020Pooled it
- Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.PharmacoEconomics · 2012Pooled it
- Hepatitis C Screening: A Health Technology Assessment.Ontario health technology assessment series · 2026Article
- Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study.Canadian journal of gastroenterology & hepatology · 2024Article
- Alcohol related disorders among elite male football players in Sweden: nationwide cohort study.BMJ (Clinical research ed.) · 2022Article
- The mean attributable health care costs associated with hepatitis B virus in Ontario, Canada: A matched cohort study.Canadian liver journal · 2022Article
- Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada.Canadian liver journal · 2021Article
- The direct healthcare costs attributable to West Nile virus illness in Ontario, Canada: a population-based cohort study using laboratory and health administrative data.BMC infectious diseases · 2019Article
- Can we afford not to screen and treat hepatitis C virus infection in Canada?Canadian liver journal · 2018Review
- Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada.Canadian liver journal · 2018Review
- Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.Annals of internal medicine · 2016Article
- Persons in correctional facilities in Canada: A key population for hepatitis C prevention and control.Canadian journal of public health = Revue canadienne de sante publique · 2015Article
- Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a population-based study.Journal of the American Heart Association · 2015Article
- Cost-effectiveness of screening for hepatitis C in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Article
- A cost-benefit/cost-effectiveness analysis of an unsanctioned supervised smoking facility in the Downtown Eastside of Vancouver, Canada.Harm reduction journal · 2014Article
- A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.Substance abuse treatment, prevention, and policy · 2014Article
- The Second Canadian Symposium on hepatitis C virus: a call to action.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Article
- Protease inhibitors for hepatitis C: economic implications.PharmacoEconomics · 2013Review
- A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada.Substance abuse treatment, prevention, and policy · 2013Article
- Mortality among British Columbians testing for hepatitis C antibody.BMC public health · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisease-specific estimates of medical costs are important for health policy decision making.
objectiveTo identify predictors of health care costs associated with hepatitis C virus (HCV) seropositivity across disease phases.
methodsHCV laboratory tests from the BC Centre for Disease Control were linked to administrative data pertaining to health services and drugs dispensed to estimate costs among case subjects and controls. The case group comprised HCV seropositive individuals (n=20,001), and the control group comprised single-tested, HCV seronegative persons (n=70,752) identified between January 1997 and December 2004. Subject observation time was assigned to the three following disease phases: initial phase (after diagnosis), late phase (late-stage liver disease) and predeath phase (12 months before death). Case subjects and controls were matched for age, sex and a propensity score within each phase to determine the net cost attributable to HCV seropositivity, and were adjusted for demographic and clinical factors.
resultsCosts increased with disease progression, with hospitalization being the highest cost component in all phases. Initial and late phase net costs (2005 Canadian dollars) were $1,850 and $6,000 per patient per year, respectively. Costs among case subjects were driven by age, comorbidities, mental illness, illicit drug use and HIV coinfection. While predeath case subject and control costs were virtually the same, costs were high and case subjects died at a younger age.
conclusionHCV seropositivity is associated with increased medical costs driven by viral sequelae and medicosocial vulnerabilities (ie, mental illness, illicit drug use and HIV coinfection). Cost mitigation and health outcome improvements will require broad-based prevention programming to reduce vulnerabilities and HCV treatment to prevent disease progression, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.